Merck Sharp & Dohme moves US court against Dr Reddy's on diabetic drugs

Updated : June 26, 2020 04:44 PM IST

Merck Sharp & Dohme Corp has moved a US court against Dr Reddy's Laboratories alleging that the Indian drug maker was planning to come out withthe generic versions of its multi-billion dollar drugs, Januvia and Janumet, before expiration ofits patent.

Merck has filed the possible patent infringement petition against Dr Reddy's in the United States District Court for the District of Delaware on four counts.

Januvia (sitagliptin phosphate) and Janumet (metformin hydrochloride and sitagliptin Phosphate), which are indicated to control high blood sugar in people with type 2 diabetes clocked over USD 5.5 billion revenues globally including USD 2.3 billion in USA in 2019.

Patents of Januvia and Janumet will expire in July 2022 for the US with six-month pediatric exclusivity, Merck said in its 2019 annual report.

Merck in its petition filed on June 23, said Dr Reddys had submitted ANDAs (abbreviated new drug application) to the US FDA seeking approval from the health regulator to engage in commercial manufacture,saleand or importation of intended generic drugs prior to expiration of the 708 patent.

Merck sought the court, among others, a preliminary and permanent injunction enjoining Dr Reddy's and all persons acting in concert with it, from the commercial manufacture, use, sale, or importation into the US the Indian drug makers ANDA Products or any other drug product covered by the patent.

UnderParagraph IVPatentCertifications, a company can seek FDA approval to market a generic drug before the expiration ofpatentsrelated to the branded medicine that the pharma company seeks to copy.

Acity-based pharmaceutical company senior official said patentinfringementcases are not uncommon for generic drug makers in the USAand thelawsuit will not have any implications on the performance of the company.

Published : June 26, 2020 04:44 PM IST

Merck Sharp & Dohme moves US court against Dr Reddy's on diabetic drugs

You May Also Like

COVID surge: Banks seek recast scheme extension in meeting with RBI

Infosys share buyback could range between $1.2 to $1.5 billion, says CLSA

Closing Bell: Sensex crashes 1,708 points, Nifty 524 as surge in COVID cases rattles investors

Trending on CNBC-TV18

recommended for you